Autonomybio develops therapeutics that target the biological mechanisms of aging to preserve muscle strength, cognitive performance, and organ resilience, aiming to extend healthspan rather than treat individual diseases. Their proprietary platform screens for molecules that modulate cellular senescence, mitochondrial function, and epigenetic stability using human-relevant organoid and animal models, and they partner with pharma and healthcare organizations to bring these interventions to market.
Funding
$17M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many adults experience a decline in physical and cognitive function as they age, leading to loss of independence, reduced quality of life, and increased healthcare costs. Current interventions often address specific diseases rather than the underlying processes of aging, leaving a gap for solutions that promote overall healthspan.
Solution
Autonomybio develops therapeutics that target the biological mechanisms of aging to preserve functional capacity and delay age‑related decline. By leveraging advances in cellular biology, epigenetic reprogramming, and metabolic modulation, the company creates interventions designed to maintain muscle strength, cognitive performance, and organ resilience. Their platform integrates preclinical models with translational pipelines to identify compounds that can safely extend healthspan. Autonomybio aims to deliver treatments that enable older adults to remain active, independent, and engaged in life‑long pursuits.
Target Audience
Primary customers are pharmaceutical partners, clinical research organizations, and healthcare providers seeking interventions that improve functional health in older adults.
Features
- Proprietary platform that screens for molecules affecting cellular senescence, mitochondrial function, and epigenetic stability
- Use of human‑relevant organoid and animal models to evaluate functional outcomes across multiple organ systems
- Biomarker‑driven approach to monitor physiological age and treatment efficacy
- Scalable manufacturing processes for small‑molecule and biologic candidates
- Regulatory‑focused development pathway targeting health‑span indications rather than single diseases